ZBTB20

Summary

ZBTB20 (zinc finger and BTB domain containing 20, HGNC:13503) is a protein-coding gene on chromosome 3q13.31, encoding Zinc finger and BTB domain-containing protein 20 (Q9HC78). May be a transcription factor that may be involved in hematopoiesis, oncogenesis, and immune responses.

This gene, which was initially designated as dendritic cell-derived BTB/POZ zinc finger (DPZF), belongs to a family of transcription factors with an N-terminal BTB/POZ domain and a C-terminal DNA-bindng zinc finger domain. The BTB/POZ domain is a hydrophobic region of approximately 120 aa which mediates association with other BTB/POZ domain-containing proteins. This gene acts as a transcriptional repressor and plays a role in many processes including neurogenesis, glucose homeostasis, and postnatal growth. Mutations in this gene have been associated with Primrose syndrome as well as the 3q13.31 microdeletion syndrome. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 26137 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Primrose syndrome (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 30
• Clinical variants (ClinVar): 466 total — 45 pathogenic, 41 likely-pathogenic
• Phenotypes (HPO): 105
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_001348800

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13503
Approved symbol	ZBTB20
Name	zinc finger and BTB domain containing 20
Location	3q13.31
Locus type	gene with protein product
Status	Approved
Aliases	ODA-8S, DKFZp566F123, DPZF
Ensembl gene	ENSG00000181722
Ensembl biotype	protein_coding
OMIM	606025
Entrez	26137

Gene structure

Transcript identifiers

Ensembl transcripts: 360 — 348 protein_coding, 12 protein_coding_CDS_not_defined

ENST00000357258, ENST00000462705, ENST00000463497, ENST00000463890, ENST00000464560, ENST00000468769, ENST00000470186, ENST00000470311, ENST00000470556, ENST00000471418, ENST00000474710, ENST00000479879, ENST00000480832, ENST00000481632, ENST00000482689, ENST00000486152, ENST00000488663, ENST00000491500, ENST00000492665, ENST00000675478, ENST00000676079, ENST00000704358, ENST00000704360, ENST00000704361, ENST00000895172, ENST00000895173, ENST00000895174, ENST00000895175, ENST00000895176, ENST00000895177, ENST00000895178, ENST00000895179, ENST00000895180, ENST00000895181, ENST00000895182, ENST00000895183, ENST00000895184, ENST00000895185, ENST00000895186, ENST00000895187, ENST00000895189, ENST00000895190, ENST00000895191, ENST00000895192, ENST00000895193, ENST00000895194, ENST00000895195, ENST00000895196, ENST00000895197, ENST00000895198, ENST00000895199, ENST00000895200, ENST00000895201, ENST00000895202, ENST00000895203, ENST00000895204, ENST00000895205, ENST00000895206, ENST00000895207, ENST00000895208, ENST00000895209, ENST00000895210, ENST00000895211, ENST00000895212, ENST00000895213, ENST00000895214, ENST00000895215, ENST00000895216, ENST00000895217, ENST00000895218, ENST00000895219, ENST00000895220, ENST00000895221, ENST00000895222, ENST00000895223, ENST00000895224, ENST00000895225, ENST00000895226, ENST00000895227, ENST00000895228, ENST00000895229, ENST00000895230, ENST00000895231, ENST00000895232, ENST00000895233, ENST00000895234, ENST00000895235, ENST00000895236, ENST00000895237, ENST00000895238, ENST00000895239, ENST00000895240, ENST00000895241, ENST00000895242, ENST00000895243, ENST00000895244, ENST00000895245, ENST00000895246, ENST00000895247, ENST00000895248, ENST00000895249, ENST00000895250, ENST00000895251, ENST00000895252, ENST00000895253, ENST00000895254, ENST00000895255, ENST00000895256, ENST00000895257, ENST00000895258, ENST00000895259, ENST00000895260, ENST00000895261, ENST00000895262, ENST00000895263, ENST00000895264, ENST00000895265, ENST00000895266, ENST00000895267, ENST00000895268, ENST00000895269, ENST00000895270, ENST00000895271, ENST00000895272, ENST00000895273, ENST00000895274, ENST00000895275, ENST00000895276, ENST00000895277, ENST00000895278, ENST00000895279, ENST00000895280, ENST00000895281, ENST00000895282, ENST00000895283, ENST00000895284, ENST00000895285, ENST00000895286, ENST00000895287, ENST00000895288, ENST00000895289, ENST00000895290, ENST00000895291, ENST00000895292, ENST00000895293, ENST00000895294, ENST00000895295, ENST00000895296, ENST00000895297, ENST00000895298, ENST00000895299, ENST00000895300, ENST00000895301, ENST00000895302, ENST00000895303, ENST00000895304, ENST00000895305, ENST00000895306, ENST00000895307, ENST00000895308, ENST00000895309, ENST00000895310, ENST00000895311, ENST00000895312, ENST00000895313, ENST00000895314, ENST00000895315, ENST00000895316, ENST00000895317, ENST00000895318, ENST00000895319, ENST00000895320, ENST00000895321, ENST00000895322, ENST00000895323, ENST00000895324, ENST00000895325, ENST00000895326, ENST00000895327, ENST00000895328, ENST00000895329, ENST00000895330, ENST00000895331, ENST00000895332, ENST00000895333, ENST00000895334, ENST00000895335, ENST00000895336, ENST00000895337, ENST00000895338, ENST00000895339, ENST00000895340, ENST00000895341, ENST00000895342, ENST00000895343, ENST00000895344, ENST00000895345, ENST00000895346, ENST00000895347, ENST00000895348, ENST00000895349, ENST00000895350, ENST00000895351, ENST00000895352, ENST00000895353, ENST00000895354, ENST00000895355, ENST00000895356, ENST00000895357, ENST00000895358, ENST00000895359, ENST00000895360, ENST00000895361, ENST00000895362, ENST00000895363, ENST00000895364, ENST00000895365, ENST00000895366, ENST00000895367, ENST00000895368, ENST00000895369, ENST00000895370, ENST00000895371, ENST00000895372, ENST00000895373, ENST00000895374, ENST00000895375, ENST00000895376, ENST00000895377, ENST00000895378, ENST00000895379, ENST00000895380, ENST00000895381, ENST00000895382, ENST00000895383, ENST00000895384, ENST00000895385, ENST00000936831, ENST00000959122, ENST00000959123, ENST00000959124, ENST00000959125, ENST00000959126, ENST00000959127, ENST00000959128, ENST00000959129, ENST00000959130, ENST00000959131, ENST00000959132, ENST00000959133, ENST00000959134, ENST00000959135, ENST00000959136, ENST00000959137, ENST00000959138, ENST00000959139, ENST00000959140, ENST00000959141, ENST00000959142, ENST00000959143, ENST00000959144, ENST00000959145, ENST00000959146, ENST00000959147, ENST00000959148, ENST00000959149, ENST00000959150, ENST00000959151, ENST00000959152, ENST00000959153, ENST00000959154, ENST00000959155, ENST00000959156, ENST00000959157, ENST00000959158, ENST00000959159, ENST00000959160, ENST00000959161, ENST00000959162, ENST00000959163, ENST00000959164, ENST00000959165, ENST00000959166, ENST00000959167, ENST00000959168, ENST00000959169, ENST00000959170, ENST00000959171, ENST00000959172, ENST00000959173, ENST00000959174, ENST00000959175, ENST00000959176, ENST00000959177, ENST00000959178, ENST00000959179, ENST00000959180, ENST00000959181, ENST00000959182, ENST00000959183, ENST00000959184, ENST00000959185, ENST00000959186, ENST00000959187, ENST00000959188, ENST00000959189, ENST00000959190, ENST00000959191, ENST00000959192, ENST00000959193, ENST00000959194, ENST00000959195, ENST00000959196, ENST00000959197, ENST00000959198, ENST00000959199, ENST00000959200, ENST00000959201, ENST00000959202, ENST00000959203, ENST00000959204, ENST00000959205, ENST00000959206, ENST00000959207, ENST00000959208, ENST00000959209, ENST00000959210, ENST00000959211, ENST00000959212, ENST00000959213, ENST00000959214, ENST00000959215, ENST00000959216, ENST00000959217, ENST00000959218, ENST00000959219, ENST00000959220, ENST00000959221, ENST00000959222, ENST00000959223, ENST00000959224, ENST00000959225, ENST00000959226, ENST00000959227, ENST00000959228, ENST00000959229, ENST00000959230, ENST00000959231, ENST00000959232, ENST00000959233, ENST00000959234, ENST00000959235, ENST00000959236, ENST00000959237, ENST00000959238, ENST00000959239, ENST00000959240, ENST00000959241, ENST00000959242, ENST00000959243

RefSeq mRNA: 17 — MANE Select: NM_001348800 NM_001164342, NM_001164343, NM_001164344, NM_001164345, NM_001164346, NM_001164347, NM_001348800, NM_001348801, NM_001348802, NM_001348803, NM_001348804, NM_001348805, NM_001393393, NM_001393394, NM_001393395, NM_001393396, NM_015642

CCDS: CCDS2981, CCDS54626

Canonical transcript exons

ENST00000675478 — 12 exons

Exon	Start	End
ENSE00001288600	114693528	114693575
ENSE00001288620	114389005	114389105
ENSE00001288629	114500352	114500391
ENSE00001421726	114900304	114900342
ENSE00001423792	114974366	114974416
ENSE00001425485	114801101	114801174
ENSE00001927190	114380777	114380940
ENSE00003518001	114380217	114380404
ENSE00003683151	114350274	114351878
ENSE00003899242	114314500	114339426
ENSE00003900755	115071219	115071414
ENSE00003902523	115147219	115147288

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 24.3908 / max 716.5414, expressed in 1584 samples.

FANTOM5 promoters (31 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43896	7.0779	1063
43923	4.3740	1072
43922	4.0162	745
43897	1.8295	736
43924	1.2867	543
43888	0.9315	207
43921	0.7929	231
43895	0.5016	256
43894	0.4629	181
43898	0.4496	240

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
corpus epididymis	UBERON:0004359	99.38	gold quality
caput epididymis	UBERON:0004358	99.30	gold quality
cauda epididymis	UBERON:0004360	99.28	gold quality
renal medulla	UBERON:0000362	98.55	gold quality
corpus callosum	UBERON:0002336	98.50	gold quality
calcaneal tendon	UBERON:0003701	98.47	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.39	gold quality
lateral globus pallidus	UBERON:0002476	98.33	gold quality
trigeminal ganglion	UBERON:0001675	98.17	gold quality
gluteal muscle	UBERON:0002000	98.16	gold quality
urethra	UBERON:0000057	98.06	gold quality
synovial joint	UBERON:0002217	98.05	gold quality
tendon	UBERON:0000043	98.02	gold quality
nipple	UBERON:0002030	97.98	gold quality
globus pallidus	UBERON:0001875	97.97	gold quality
inferior vagus X ganglion	UBERON:0005363	97.91	gold quality
medial globus pallidus	UBERON:0002477	97.89	gold quality
saphenous vein	UBERON:0007318	97.80	gold quality
dorsal root ganglion	UBERON:0000044	97.79	gold quality
lower lobe of lung	UBERON:0008949	97.78	gold quality
tibia	UBERON:0000979	97.76	gold quality
biceps brachii	UBERON:0001507	97.74	gold quality
cranial nerve II	UBERON:0000941	97.73	gold quality
ventral tegmental area	UBERON:0002691	97.62	gold quality
vena cava	UBERON:0004087	97.59	gold quality
triceps brachii	UBERON:0001509	97.58	gold quality
medulla oblongata	UBERON:0001896	97.43	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.35	gold quality
mammary duct	UBERON:0001765	97.32	gold quality
subthalamic nucleus	UBERON:0001906	97.28	gold quality

Single-cell (SCXA)

Detected in 18 experiment(s), a significant marker in 17.

Experiment	Marker?	Max mean expression
E-MTAB-6819	yes	8604.47
E-CURD-119	yes	6131.92
E-MTAB-8142	yes	962.99
E-MTAB-11121	yes	859.61
E-HCAD-35	yes	83.13
E-HCAD-25	yes	54.46
E-HCAD-6	yes	37.39
E-GEOD-84465	yes	26.55
E-HCAD-5	yes	24.35
E-MTAB-10553	yes	22.96
E-GEOD-81608	yes	18.23
E-MTAB-8410	yes	17.79
E-MTAB-9543	yes	13.76
E-CURD-46	yes	9.87
E-MTAB-6678	yes	9.63

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
AFP	Repression
FBP1
NFKBIA	Repression

Upstream regulators (CollecTRI, top): IRF4, NR1I2

miRNA regulators (miRDB)

908 targeting ZBTB20, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-450A-1-3P	100.00	69.33	1837

Literature-anchored findings (GeneRIF, showing 35)

• Misexpression of Zbtb20 in transgenic mice converts the normal cytoarchitectonic organization of the subiculum, postsubiculum, and granular retrosplenial cortex to a CA1-like stratum pyramidale. (PMID:19955470)
• ZBTB20 mRNA & protein expression were elevated significantly in HCC tissues compared with the paired non-tumor tissues & normal liver. HCC recurrence or metastasis increased & disease-free survival decreased with high ZBTB20 expression. (PMID:21702992)
• We identified new susceptibility loci for non-cardia gastric cancer at 3q13.31: rs9841504 in ZBTB20 (PMID:22037551)
• This study disclosed Zbtb20-mediated transcriptional repressor mechanism may be involved in development of the human archicortex. (PMID:23283686)
• Polymorphism in ZBTB20 gene is associated with gastric cancer. (PMID:23861218)
• Major depressive disorder is associated with significant hypermethylation within the coding region of ZBTB20. (PMID:24694013)
• Missense mutations in ZBTB20 underlie Primrose syndrome. (PMID:25017102)
• 3q13.31 microdeletion-based dosage imbalance of ZBTB20 linked to a range of neurodevelopmental, cognitive and psychiatric disorders, likely mediated by dysregulation of multiple ZBTB20 target genes. (PMID:25062845)
• important role for ZBTB20 in controlling NSCLC development (PMID:25311537)
• High ZBTB20 expression is associated with hepatocellular carcinoma. (PMID:26893361)
• We report a boy with intellectual disability carrying two de novo missense mutations in the last exon of ZBTB20 (Ser616Phe and Gly741Arg; both previously unreported). One of them, Ser616Phe, affects an amino acid located in one of the C2H2 zing-fingers involved in DNA-binding and close to other missense mutations already described. Reverse phenotyping showed that this patient presents with classic features of Primrose syn (PMID:27061120)
• ZBTB20 rs9841504 polymorphism is a protective factor for gastric cancer rather than esophageal cancer. (PMID:27646774)
• we report novel de novo ZBTB20 mutations in three independent cases with characteristic features of Primrose syndrome including constant CCA. (PMID:29681083)
• Our data document that both mutations have dominant negative impact on wild-type ZBTB20, providing further evidence of the specific behavior of Primrose syndrome (PS)-causing mutations on ZBTB20 function. (PMID:29737001)
• ZBTB20 knockdown inhibited glioblastoma cell proliferation, migration, and invasion. (PMID:30099442)
• ZBTB20 is a candidate susceptibility gene for seasonal affective disorder (PMID:30217971)
• Two ZBTB20 single nucleotide variants, located at the N-terminal and central regions of the protein and potentially conferring autism risk, altered dendritic spine morphology. In contrast, a single nucleotide variant identified in patients with intellectual disability and located at the C-terminus of ZBTB20 affected dendritic arborization and dendritic length but had no effect on dendritic spine morphology (PMID:30281617)
• Long non-coding RNA LINC00641 promotes cell growth and migration through modulating miR-378a/ZBTB20 axis in acute myeloid leukemia. (PMID:31539138)
• an important role for ZBTB20 in controlling gastric cancer development (PMID:31556767)
• Primrose syndrome associated with unclassified immunodeficiency and a novel ZBTB20 mutation. (PMID:31821719)
• Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20. (PMID:32071410)
• The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia. (PMID:32238402)
• Primrose syndrome: Characterization of the phenotype in 42 patients. (PMID:32266967)
• HBV DNA integrates into upregulated ZBTB20 in patients with hepatocellular carcinoma. (PMID:32319639)
• Prediction of gastric cancer risk: association between ZBTB20 genetic variance and gastric cancer risk in Chinese Han population. (PMID:32936247)
• LncRNA SNHG8 promotes cell migration and invasion in breast cancer cell through miR-634/ZBTB20 axis. (PMID:33275231)
• ZBTB20 Positively Regulates Oxidative Stress, Mitochondrial Fission, and Inflammatory Responses of ox-LDL-Induced Macrophages in Atherosclerosis. (PMID:33777314)
• An association study in the Taiwan Biobank elicits three novel candidates for cognitive aging in old adults: NCAM1, TTC12 and ZBTB20. (PMID:34285142)
• Circ-SFMBT2 facilitates the malignant growth of acute myeloid leukemia cells by modulating miR-582-3p/ZBTB20 pathway. (PMID:34825699)
• Spatial control of astrogenesis progression by cortical arealization genes. (PMID:35818636)
• The long non-coding RNA KLF3-AS1/miR-10a-3p/ZBTB20 axis improves the degenerative changes in human nucleus pulposus cells. (PMID:37052702)
• Circ_0001602 aggravates the progression of acute myeloid leukemia by regulating the miR-192-5p/ZBTB20 axis. (PMID:37585722)
• Transcription Factor Zbtb20 as a Regulator of Malignancy and Its Practical Applications. (PMID:37762065)
• Zinc Finger and BTB Domain-Containing 20: A Newly Emerging Player in Pathogenesis and Development of Human Cancers. (PMID:38397429)
• [Le miR-224-5p regule sert de biomarqueur pour l’insuffisance hepatique aigue pediatrique et regule l’inflammation en modulant ZBTB20]. (PMID:38638020)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zbtb20	ENSDARG00000005586
mus_musculus	Zbtb20	ENSMUSG00000022708
rattus_norvegicus	Zbtb20	ENSRNOG00000056716

Paralogs (36): ZBTB32 (ENSG00000011590), SNAI2 (ENSG00000019549), PRDM1 (ENSG00000057657), PRDM6 (ENSG00000061455), ZNF76 (ENSG00000065029), PATZ1 (ENSG00000100105), MAZ (ENSG00000103495), ZBTB16 (ENSG00000109906), ZNF451 (ENSG00000112200), ZBTB45 (ENSG00000119574), ZNF410 (ENSG00000119725), SNAI1 (ENSG00000124216), ZNF384 (ENSG00000126746), ZBTB1 (ENSG00000126804), VEZF1 (ENSG00000136451), PRDM14 (ENSG00000147596), ZNF276 (ENSG00000158805), ZNF362 (ENSG00000160094), ZNF653 (ENSG00000161914), ZNF281 (ENSG00000162702), ZNF148 (ENSG00000163848), ZNF143 (ENSG00000166478), HIC2 (ENSG00000169635), PRDM10 (ENSG00000170325), ZNF296 (ENSG00000170684), ZNF692 (ENSG00000171163), ZNF575 (ENSG00000176472), HIC1 (ENSG00000177374), ZBTB18 (ENSG00000179456), ZBTB42 (ENSG00000179627), ZBTB7C (ENSG00000184828), SNAI3 (ENSG00000185669), ZFP91 (ENSG00000186660), MTF1 (ENSG00000188786), SCRT2 (ENSG00000215397), SCRT1 (ENSG00000261678)

Protein

Protein identifiers

Zinc finger and BTB domain-containing protein 20 — Q9HC78 (reviewed: Q9HC78)

Alternative names: Dendritic-derived BTB/POZ zinc finger protein, Zinc finger protein 288

All UniProt accessions (4): Q9HC78, A0A994J4D3, C9JCX0, C9JUH0

UniProt curated annotations — full annotation on UniProt →

Function. May be a transcription factor that may be involved in hematopoiesis, oncogenesis, and immune responses. Plays a role in postnatal myogenesis, may be involved in the regulation of satellite cells self-renewal.

Subunit / interactions. Can homodimerize. Binds to DNA.

Subcellular location. Nucleus.

Tissue specificity. Expressed in spleen, lymph node, thymus, peripheral blood leukocytes, and fetal liver.

Post-translational modifications. Sumoylated with SUMO1.

Disease relevance. Primrose syndrome (PRIMS) [MIM:259050] A disease characterized by macrocephaly, intellectual disability, disturbed behavior, dysmorphic facial features, ectopic calcifications, large calcified ear auricles, and progressive muscle wasting. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HC78-1	1	yes
Q9HC78-2	2

RefSeq proteins (17): NP_001157814, NP_001157815, NP_001157816, NP_001157817, NP_001157818, NP_001157819, NP_001335729, NP_001335730, NP_001335731, NP_001335732, NP_001335733, NP_001335734, NP_001380322, NP_001380323, NP_001380324, NP_001380325, NP_056457 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000210	BTB/POZ_dom	Domain
IPR011333	SKP1/BTB/POZ_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050457	ZnFinger_BTB_dom_contain	Family

Pfam: PF00096, PF00651

UniProt features (36 total): sequence conflict 7, compositionally biased region 5, modified residue 5, zinc finger region 5, cross-link 4, sequence variant 4, region of interest 3, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9KH2	X-RAY DIFFRACTION	2.59
9JZT	X-RAY DIFFRACTION	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HC78-F1	53.05	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (9): 211, 353, 357, 690, 695, 330, 330, 371, 723

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 965 (showing top): AHRARNT_01, WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, GOBP_NUCLEOSIDE_DIPHOSPHATE_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TYPE_I_INTERFERON_PRODUCTION, BASSO_B_LYMPHOCYTE_NETWORK, XU_GH1_AUTOCRINE_TARGETS_UP, GOBP_CELLULAR_RESPONSE_TO_CARBOHYDRATE_STIMULUS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, HASLINGER_B_CLL_WITH_MUTATED_VH_GENES, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, LHX3_01, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND

GO Biological Process (12): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of cytokine production (GO:0001817), regulation of immune system process (GO:0002682), negative regulation of gene expression (GO:0010629), positive regulation of interferon-beta production (GO:0032728), positive regulation of interleukin-6 production (GO:0032755), positive regulation of tumor necrosis factor production (GO:0032760), positive regulation of glycolytic process (GO:0045821), positive regulation of lipid biosynthetic process (GO:0046889), lipid homeostasis (GO:0055088), cellular response to glucose stimulus (GO:0071333), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (8): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), nuclear body (GO:0016604)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of gene expression	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
cellular anatomical structure	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
cytokine production	1
regulation of multicellular organismal process	1
immune system process	1
regulation of biological process	1
gene expression	1
negative regulation of macromolecule biosynthetic process	1
positive regulation of type I interferon production	1
interferon-beta production	1
regulation of interferon-beta production	1
positive regulation of cytokine production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
positive regulation of tumor necrosis factor superfamily cytokine production	1
glycolytic process	1
regulation of glycolytic process	1
positive regulation of purine nucleotide catabolic process	1
positive regulation of carbohydrate metabolic process	1
positive regulation of ATP metabolic process	1
lipid biosynthetic process	1
positive regulation of biosynthetic process	1
positive regulation of lipid metabolic process	1
regulation of lipid biosynthetic process	1
chemical homeostasis	1
intracellular glucose homeostasis	1
response to glucose	1
cellular response to hexose stimulus	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
cis-regulatory region sequence-specific DNA binding	1

Protein interactions and networks

STRING

1608 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZBTB20	ZHX2	Q9Y6X8	847
ZBTB20	AFP	P02771	774
ZBTB20	GGT1	P19440	666
ZBTB20	AFM	P43652	566
ZBTB20	SOX5	P35711	524
ZBTB20	SATB2	Q9UPW6	497
ZBTB20	IGFALS	P35858	490
ZBTB20	IGFBP2	P18065	464
ZBTB20	CPT1A	P50416	444
ZBTB20	ALB	P02768	443
ZBTB20	FASN	P49327	443
ZBTB20	UNC5CL	Q8IV45	436
ZBTB20	LHX5	Q9H2C1	427
ZBTB20	IGF1	P01343	426
ZBTB20	CALB1	P05937	416
ZBTB20	POGZ	Q7Z3K3	416

IntAct

27 interactions, top by confidence:

A	B	Type	Score
HSPB8	VWA8	psi-mi:“MI:0914”(association)	0.530
MBD3L1	CDK2AP1	psi-mi:“MI:0914”(association)	0.530
DNAJB8	DNAJB6	psi-mi:“MI:0914”(association)	0.530
TEAD2	TEAD1	psi-mi:“MI:0914”(association)	0.530
HSP90AB1	ZBTB20	psi-mi:“MI:0915”(physical association)	0.400
ZBTB20	CDC37	psi-mi:“MI:0915”(physical association)	0.400
NR3C1	ZBTB20	psi-mi:“MI:0915”(physical association)	0.370
PPARG	ZBTB20	psi-mi:“MI:0915”(physical association)	0.370
	TNFRSF10A	psi-mi:“MI:0914”(association)	0.350
BORCS8	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
FOXF2	POTEF	psi-mi:“MI:0914”(association)	0.350
CLASRP	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
SENP3	IPO5	psi-mi:“MI:0914”(association)	0.350
INKA1	SDCBP	psi-mi:“MI:0914”(association)	0.350
SYT11	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
CST11	PLXNB2	psi-mi:“MI:0914”(association)	0.350
TFPT	CCP110	psi-mi:“MI:0914”(association)	0.350
MECOM	MTA2	psi-mi:“MI:0914”(association)	0.350
TRNAU1AP	SLC25A4	psi-mi:“MI:0914”(association)	0.350
TWIST2	TCF3	psi-mi:“MI:0914”(association)	0.350
DACT2	MLYCD	psi-mi:“MI:0914”(association)	0.350
AFG2B	MMP24OS	psi-mi:“MI:0914”(association)	0.350
DNAJB9	PC	psi-mi:“MI:0914”(association)	0.350
RBM11	KLK10	psi-mi:“MI:0914”(association)	0.350
SYT11	PJA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (43): ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-RNA), ZBTB20 (PCA), ZBTB20 (Affinity Capture-RNA), ZBTB20 (Affinity Capture-MS), ZBTB20 (Affinity Capture-MS)

ESM2 similar proteins: A0JN76, A1L2U9, B1WAZ8, B1WBU4, O15060, O35260, O43298, O93567, P14404, P41182, P41183, Q05516, Q0IH98, Q0IJ29, Q0P4X6, Q0V8G8, Q0VCJ6, Q15916, Q1L8W0, Q3B725, Q3SWU4, Q5TC79, Q5ZM39, Q6NRM8, Q6P882, Q6YND2, Q7TQG0, Q7TSZ8, Q7ZWZ4, Q801P1, Q80X44, Q86UZ6, Q8BID6, Q8CII0, Q8K088, Q8K0L9, Q8N680, Q8NAP8, Q8NCN2, Q8NCP5

Diamond homologs: A0A0A6YY25, B2RXH4, E0CZ16, E1B932, E7F6F9, F1LZ52, F1LZF0, F1MBP6, O88282, O93567, O95198, P10074, P17789, P42282, P42283, P42284, Q01295, Q1H9T6, Q24174, Q24206, Q3B7M1, Q52KG4, Q53G59, Q53HC5, Q5R633, Q5REP9, Q5U374, Q66HD2, Q6NRH0, Q7KQZ4, Q7KRI2, Q867Z4, Q86B87, Q8BGY4, Q8BZM0, Q8CA72, Q8IN81, Q8JZP3, Q8K0L9, Q8N143

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
ZBTB20	“down-regulates quantity by repression”	AFP	“transcriptional regulation”
ZBTB20	“down-regulates quantity by repression”	NFKBIA	“transcriptional regulation”
ZBTB20	up-regulates	Neurogenesis

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — LGGNOS.

Clinical variants and AI predictions

ClinVar

466 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	45
Likely pathogenic	41
Uncertain significance	171
Likely benign	140
Benign	23

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1339418	NM_001348800.3(ZBTB20):c.1727dup (p.Pro577fs)	Pathogenic
139436	NM_001348800.3(ZBTB20):c.1768A>C (p.Lys590Gln)	Pathogenic
139437	NM_001348800.3(ZBTB20):c.1771C>G (p.Gln591Glu)	Pathogenic
139438	NM_001348800.3(ZBTB20):c.1787A>G (p.His596Arg)	Pathogenic
139446	NM_001348800.3(ZBTB20):c.1802C>T (p.Thr601Ile)	Pathogenic
139447	NM_001348800.3(ZBTB20):c.1805G>C (p.Gly602Ala)	Pathogenic
139449	NM_001348800.3(ZBTB20):c.1861C>T (p.Leu621Phe)	Pathogenic
139450	NM_001348800.3(ZBTB20):c.1876G>A (p.Val626Met)	Pathogenic
1686308	NM_001348800.3(ZBTB20):c.1817A>G (p.His606Arg)	Pathogenic
1691860	NM_001348800.3(ZBTB20):c.1916G>T (p.Cys639Phe)	Pathogenic
1712590	NM_001348800.3(ZBTB20):c.1739G>A (p.Cys580Tyr)	Pathogenic
1712633	NM_001348800.3(ZBTB20):c.1871A>C (p.His624Pro)	Pathogenic
1804424	NM_001348800.3(ZBTB20):c.1795G>T (p.Val599Leu)	Pathogenic
2010903	NM_001348800.3(ZBTB20):c.1635dup (p.Gly546fs)	Pathogenic
2023798	NM_001348800.3(ZBTB20):c.1852A>G (p.Lys618Glu)	Pathogenic
2024704	NM_001348800.3(ZBTB20):c.1860C>G (p.Tyr620Ter)	Pathogenic
2229580	NM_001348800.3(ZBTB20):c.1412dup (p.Ser472fs)	Pathogenic
2442541	NM_001348800.3(ZBTB20):c.1906T>C (p.Cys636Arg)	Pathogenic
2443883	NM_001348800.3(ZBTB20):c.1024del (p.Gln342fs)	Pathogenic
2578946	NM_001348800.3(ZBTB20):c.1832G>A (p.Cys611Tyr)	Pathogenic
2766516	NM_001348800.3(ZBTB20):c.621_622insCCGCGGGGCACTGGGG (p.Gly208fs)	Pathogenic
2883999	NM_001348800.3(ZBTB20):c.1879A>G (p.Thr627Ala)	Pathogenic
2921295	NM_001348800.3(ZBTB20):c.1967A>G (p.His656Arg)	Pathogenic
3246964	NC_000003.11:g.(?114057852)(114070745_?)del	Pathogenic
3342469	NM_001348800.3(ZBTB20):c.721G>T (p.Asp241Tyr)	Pathogenic
3361980	NM_001348800.3(ZBTB20):c.1915T>G (p.Cys639Gly)	Pathogenic
3372559	NM_001348800.3(ZBTB20):c.1177C>T (p.Gln393Ter)	Pathogenic
3377070	NM_001348800.3(ZBTB20):c.388C>T (p.Gln130Ter)	Pathogenic
3633366	NM_001348800.3(ZBTB20):c.1787A>C (p.His596Pro)	Pathogenic
3660416	NM_001348800.3(ZBTB20):c.691dup (p.Tyr231fs)	Pathogenic

SpliceAI

5787 predictions. Top by Δscore:

Variant	Effect	Δscore
3:114339435:G:GC	acceptor_gain	1.0000
3:114380216:CAAT:C	donor_gain	1.0000
3:114389003:A:AC	donor_gain	1.0000
3:114389004:C:CC	donor_gain	1.0000
3:114500346:ACTT:A	donor_loss	1.0000
3:114500348:TTAC:T	donor_loss	1.0000
3:114500349:TA:T	donor_loss	1.0000
3:114500350:A:AC	donor_gain	1.0000
3:114500350:A:AT	donor_loss	1.0000
3:114500351:C:CA	donor_gain	1.0000
3:114500351:C:T	donor_loss	1.0000
3:114339422:CTCAC:C	acceptor_gain	0.9900
3:114339423:TCAC:T	acceptor_gain	0.9900
3:114339424:CAC:C	acceptor_gain	0.9900
3:114339424:CACC:C	acceptor_gain	0.9900
3:114339425:AC:A	acceptor_gain	0.9900
3:114339426:CCTGT:C	acceptor_gain	0.9900
3:114339427:C:A	acceptor_loss	0.9900
3:114339430:T:TC	acceptor_gain	0.9900
3:114339433:A:AC	acceptor_gain	0.9900
3:114339435:G:C	acceptor_gain	0.9900
3:114339447:A:T	acceptor_gain	0.9900
3:114339469:A:C	acceptor_gain	0.9900
3:114350269:CTCA:C	donor_loss	0.9900
3:114350270:TCACC:T	donor_loss	0.9900
3:114350271:CA:C	donor_loss	0.9900
3:114350272:A:C	donor_loss	0.9900
3:114351882:CAGCA:C	acceptor_gain	0.9900
3:114351885:CA:C	acceptor_gain	0.9900
3:114351886:A:C	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000002469 (3:114953102 T>C), RS1000003997 (3:114744817 C>T), RS1000004596 (3:114616706 C>T), RS1000006675 (3:114789848 T>C), RS1000013401 (3:114664398 A>G), RS1000018722 (3:115060390 T>C,G), RS1000021704 (3:114566474 T>C,G), RS1000024742 (3:114522614 G>A), RS1000028852 (3:114477669 A>C,T), RS1000031727 (3:114927908 C>G), RS1000034072 (3:114854942 C>T), RS1000037674 (3:115106311 G>A), RS1000039838 (3:114802189 G>C), RS1000048324 (3:114836958 T>C), RS1000048817 (3:114546527 T>G)

Disease associations

OMIM: gene MIM:606025 | disease phenotypes: MIM:259050, MIM:269880

GenCC curated gene-disease

Disease	Classification	Inheritance
Primrose syndrome	Definitive	Autosomal dominant
diabetes mellitus	Strong	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
Primrose syndrome	Definitive	AD

Mondo (6): Primrose syndrome (MONDO:0009798), intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092), autism spectrum disorder (MONDO:0005258), SHORT syndrome (MONDO:0010026), diabetes mellitus (MONDO:0005015)

Orphanet (4): Intellectual disability-cataracts-calcified pinnae-myopathy syndrome (Orphanet:3042), SHORT syndrome (Orphanet:3163), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

105 total (30 of 105 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000028	Cryptorchidism
HP:0000135	Hypogonadism
HP:0000160	Narrow mouth
HP:0000174	Abnormal palate morphology
HP:0000179	Thick lower lip vermilion
HP:0000218	High palate
HP:0000238	Hydrocephalus
HP:0000248	Brachycephaly
HP:0000256	Macrocephaly
HP:0000272	Malar flattening
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000327	Hypoplasia of the maxilla
HP:0000337	Broad forehead
HP:0000365	Hearing impairment
HP:0000400	Macrotia
HP:0000405	Conductive hearing impairment
HP:0000431	Wide nasal bridge
HP:0000455	Broad nasal tip
HP:0000463	Anteverted nares
HP:0000486	Strabismus
HP:0000490	Deeply set eye
HP:0000494	Downslanted palpebral fissures
HP:0000508	Ptosis
HP:0000518	Cataract
HP:0000664	Synophrys
HP:0000711	Restlessness
HP:0000717	Autism
HP:0000718	Aggressive behavior

GWAS associations

30 associations (top):

Study	Trait	p-value
GCST001300_1	Gastric cancer	2.000000e-09
GCST002616_4	Mitochondrial DNA levels	3.000000e-06
GCST002828_21	Urate levels in obese individuals	5.000000e-06
GCST002976_8	HIV-1 viral setpoint	8.000000e-07
GCST003400_23	Type 2 diabetes	3.000000e-06
GCST006411_2	Mucinous adenocarcinoma in colorectal cancer	1.000000e-06
GCST006411_3	Mucinous adenocarcinoma in colorectal cancer	2.000000e-06
GCST006624_95	Systolic blood pressure	1.000000e-08
GCST007102_10	Seasonality and depression	2.000000e-06
GCST007102_8	Seasonality and depression	4.000000e-06
GCST007102_9	Seasonality and depression	8.000000e-07
GCST007324_116	Adventurousness	1.000000e-08
GCST007324_137	Adventurousness	2.000000e-09
GCST007325_160	General risk tolerance (MTAG)	1.000000e-11
GCST007325_202	General risk tolerance (MTAG)	2.000000e-08
GCST007327_76	Smoking status (ever vs never smokers)	4.000000e-08
GCST007978_2	Postoperative atrial fibrillation after cardiac surgery	8.000000e-07
GCST008646_6	Gastric cancer	4.000000e-06
GCST010118_23	Type 2 diabetes	2.000000e-11
GCST010135_51	Oily fish consumption	5.000000e-08
GCST010140_41	Pork consumption	5.000000e-08
GCST010142_37	Fish- and plant-related diet	9.000000e-09
GCST010242_229	HDL cholesterol levels	1.000000e-08
GCST010988_110	Adult body size	8.000000e-11
GCST011011_22	Youthful appearance (self-reported)	5.000000e-17
GCST011703_62	Smoking initiation	3.000000e-10
GCST90002400_367	Plateletcrit	1.000000e-12
GCST90002402_317	Platelet count	3.000000e-10
GCST90011900_22	Serum alkaline phosphatase levels	3.000000e-14
GCST90014033_25	Haemorrhoidal disease	2.000000e-09

EFO canonical traits (16, from GWAS)

EFO ID	Trait name
EFO:0006312	mitochondrial DNA measurement
EFO:0004531	urate measurement
EFO:0006319	HIV viral set point measurement
EFO:0009361	colorectal mucinous adenocarcinoma
EFO:0006335	systolic blood pressure
EFO:0006876	seasonality measurement
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0009951	response to surgery
EFO:0009952	post-operative atrial fibrillation
EFO:0008111	diet measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0005670	smoking initiation
EFO:0007985	platelet crit
EFO:0004309	platelet count
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D003920	Diabetes Mellitus	C18.452.394.750; C19.246
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625
C536420	Primrose syndrome (supp.)
C537327	SHORT syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

66 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	6
methylmercuric chloride	decreases expression, increases expression, affects cotreatment	4
Aflatoxin B1	increases expression, increases methylation, decreases expression, decreases methylation	4
bisphenol A	increases methylation, affects cotreatment, decreases expression, decreases methylation	3
sodium arsenite	increases expression, affects methylation	3
bisphenol F	affects cotreatment, decreases methylation, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
bisphenol S	increases methylation, affects cotreatment, decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Air Pollutants	decreases expression, affects expression, increases abundance	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Cisplatin	affects cotreatment, decreases expression	2
Folic Acid	affects cotreatment, increases expression, decreases expression	2
Nickel	decreases expression	2
Cyclosporine	decreases expression, increases expression, increases methylation	2
GSK-J4	increases expression	1
TAK-243	decreases sumoylation	1
bufotalin	decreases expression	1
triphenyl phosphate	affects expression	1
geraniol	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
resorcinol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XV88	HEK293 eGFP-ZBTB20	Transformed cell line	Female

Clinical trials (associated diseases)

598 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00044746	PHASE4	COMPLETED	Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections
NCT00069602	PHASE4	COMPLETED	Assessing Continuous Glucose Monitors in Healthy Children
NCT00079638	PHASE4	COMPLETED	Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00095446	PHASE4	COMPLETED	NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00101751	PHASE4	COMPLETED	INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study
NCT00108615	PHASE4	COMPLETED	Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
NCT00117780	PHASE4	COMPLETED	Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
NCT00120341	PHASE4	COMPLETED	Anodyne Therapy in Diabetic Sensory Neuropathy
NCT00121355	PHASE4	COMPLETED	Novofine Autocover Safety Needle Versus BD Safety Glide
NCT00135226	PHASE4	ACTIVE_NOT_RECRUITING	ASCEND: A Study of Cardiovascular Events iN Diabetes
NCT00144937	PHASE4	UNKNOWN	Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease
NCT00147251	PHASE4	COMPLETED	Stop Atherosclerosis in Native Diabetics Study
NCT00157638	PHASE4	COMPLETED	Integrating Family Medicine and Pharmacy to Advance Primary Care Therapeutics
NCT00162344	PHASE4	COMPLETED	A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease.
NCT00177138	PHASE4	TERMINATED	Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
NCT00182494	PHASE4	UNKNOWN	Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00184561	PHASE4	COMPLETED	Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
NCT00184626	PHASE4	COMPLETED	Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
NCT00202618	PHASE4	UNKNOWN	Rationale and Design for Shiga Microalbuminuria Reduction Trial
NCT00209170	PHASE4	COMPLETED	Depression-Diabetes Mechanisms: Urban African Americans
NCT00209417	PHASE4	TERMINATED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
NCT00212004	PHASE4	TERMINATED	Pioglitazone Protects Diabetes Mellitus (DM) Patients Against Re-Infarction (PPAR Study)
NCT00219440	PHASE4	COMPLETED	A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS
NCT00225849	PHASE4	UNKNOWN	Japanese Primary Prevention Project With Aspirin
NCT00231894	PHASE4	COMPLETED	Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia
NCT00234871	PHASE4	COMPLETED	Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
NCT00235014	PHASE4	COMPLETED	A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
NCT00236379	PHASE4	COMPLETED	A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
NCT00241904	PHASE4	COMPLETED	Reducing Total Cardiovascular Risk in an Urban Community
NCT00263393	PHASE4	COMPLETED	Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS)
NCT00264901	PHASE4	COMPLETED	Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
NCT00274274	PHASE4	COMPLETED	Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
NCT00282451	PHASE4	COMPLETED	Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes
NCT00282659	PHASE4	COMPLETED	The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
NCT00287820	PHASE4	COMPLETED	Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
NCT00295555	PHASE4	COMPLETED	Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
NCT00299169	PHASE4	TERMINATED	Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes
NCT00301392	PHASE4	COMPLETED	Japan Prevention Trial of Diabetes by Pitavastatin in Patients With Impaired Glucose Tolerance (J-PREDICT)
NCT00306696	PHASE4	COMPLETED	Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
NCT00309465	PHASE4	COMPLETED	Perioperative Insulin Glargine Dosing Study